8-K: Cocrystal Pharma to Present at NobleCon 21

Cocrystal Pharma's CFO and Co-CEO, James Martin, will present a company overview and clinical progress update at the Noble Capital Markets 21st Emerging Growth Equity Conference on December 3, 2025.

Summary

• Cocrystal Pharma, Inc. (Nasdaq: COCP) announced that James Martin, its Chief Financial Officer and Co-Chief Executive Officer, will present at the Noble Capital Markets 21st Emerging Growth Equity Conference.
• The presentation is scheduled for Wednesday, December 3, 2025, at 10:00 am Eastern time.
• Mr. Martin will provide a company overview and a clinical progress update.
• The conference, NobleCon 21, is being held at the Executive Education Complex of Florida Atlantic University in Boca Raton, Florida.
• A video webcast of the presentation will be available on December 4, 2025, on the company's website and will be archived for 90 days.
• Interested investors can attend the conference at a discounted rate using the code COCPNOBLECON.

Sentiment

Score: 5

Explanation: Neutral, as the filing announces an upcoming investor presentation rather than providing new financial or clinical results. It's a routine corporate communication for a public company.

Positives

• The company is actively engaging with the investment community by presenting at a recognized emerging growth equity conference, which can enhance visibility and investor interest.
• The presentation will include a clinical progress update, offering potential insights into the company's drug development pipeline.

Negatives

• The filing itself does not contain new financial results or clinical data, only an announcement of an upcoming event.

Future Outlook

The filing announces an upcoming investor presentation where the company's CFO and Co-CEO will provide a clinical progress update, which is expected to include forward-looking information regarding the company's drug development pipeline.

Industry Context

Clinical-stage biotechnology companies frequently present at investor conferences to attract capital, update stakeholders on pipeline progress, and increase market visibility. Participation in events like Noble Capital Markets' Emerging Growth Equity Conference is a standard practice for companies seeking to engage with institutional and retail investors interested in high-growth sectors like biotech.

Stakeholder Impact

• Shareholders will have an opportunity to receive updates on the company's clinical progress and strategic direction through the upcoming presentation and its webcast.
• Potential new investors may be attracted to the company through its participation in the conference and the information shared.

Next Steps

• James Martin, CFO and Co-CEO, will present a company overview and clinical progress update at NobleCon 21 on December 3, 2025.
• A video webcast of the presentation will be made available on the company's website on December 4, 2025, and archived for 90 days.

Key Dates

Recommendation

The filing is an announcement of an upcoming investor presentation and does not contain new financial results, clinical data, or strategic shifts that would warrant a change in investment recommendation at this time. Investors should await the presentation for potential new information before making any investment decisions.

Keywords

Biotechnology, Antiviral, Clinical-stage, Conference, Investor Presentation, COCP, NobleCon, Drug Development